CXCL8 Facilitates the Survival and Paclitaxel-Resistance of Triple-Negative Breast Cancers [0.03%]
CXCL8促进三阴性乳腺癌的存活和紫杉醇耐药性
Maolin Yi,Chengcheng Peng,Bingxiang Xia et al.
Maolin Yi et al.
Background: This study aimed to demonstrate CXCL8 expression in TNBC tissues and cells, and elucidate the functional mechanism of CXCL8 in paclitaxel (PTX)-resistant TNBC. ...
miR-875 Serves as A Candidate Biomarker for Detection and Prognosis and Is Correlated with PHH3 Index Levels in Breast Cancer Patients [0.03%]
microRNA-875可作为乳腺癌检测及预后的候选标志物并与PHH3指数相关
Xiaokang Liu,Mengshu Liu,Haiming Ma et al.
Xiaokang Liu et al.
Background: miRNAs play crucial roles in cancers. This study investigated the potential value of miR-875 to be a detective or/and prognostic marker and evaluate the correlation between its expression and PHH3 index levels...
Feasibility of an Online Patient Community to Support Older Women With Newly Diagnosed Breast Cancer [0.03%]
在线患者社区支持新诊断乳腺癌老年妇女的可行性研究
Rachel H Occhiogrosso,Siyang Ren,Nabihah Tayob et al.
Rachel H Occhiogrosso et al.
Background: We conducted a feasibility study of integrating a free, online patient health community, PatientsLikeMe (PLM), into the neo/adjuvant care of older patients recently diagnosed with breast cancer. We assessed wh...
Effect of Tart Cherry on Aromatase Inhibitor-Induced Arthralgia (AIA) in Nonmetastatic Hormone-Positive Breast Cancer Patients: A Randomized Double-Blind Placebo-Controlled Trial [0.03%]
山查对非转移性激素阳性乳腺癌患者芳香化酶抑制剂致关节痛(AIA)的影响：随机双盲安慰剂对照试验
Mina Shenouda,Renee Copley,Toni Pacioles et al.
Mina Shenouda et al.
Background: Aromatase Inhibitor induced Arthralgia (AIA) can cause noncompliance leading to decreased breast-cancer survival. Effective interventions for AIA are limited. Tart cherry (TC) showed beneficial effect on muscu...
Randomized Controlled Trial
Clinical breast cancer. 2022 Jan;22(1):e30-e36. DOI:10.1016/j.clbc.2021.06.007 2022
Downregulation of PDGF-D Inhibits Proliferation and Invasion in Breast Cancer MDA-MB-231 Cells [0.03%]
PDGF-D低表达抑制乳腺癌MDA-MB-231细胞增殖和侵袭能力
Jing-Feng Lu,Zhi-Qiu Hu,Meng-Xuan Yang et al.
Jing-Feng Lu et al.
Background: The platelet derived growth factor-D (PDGF-D) plays an important role in breast tumor aggressiveness. However, limited study has investigated the effect of silencing PDGF-D on the biological function of breast...
Has Hypofractionated Whole-Breast Radiation Therapy Become the Standard of Care in the United States? An Updated Report from National Cancer Database [0.03%]
美国全国癌症数据库更新报告：低剂量全乳房放射治疗已成为标准护理吗？
Minji M Kang,Yasmin Hasan,Joseph Waller et al.
Minji M Kang et al.
Introduction/background: We aimed to update the previous evaluation of hypofractionated whole-breast irradiation (HF-WBI) use over time in the United States and factors related to its adoption for patients undergoing a lu...
Long-Term Outcomes Using Electron IOERT APBI for Early Stage Breast Cancer: The Verona University Hospital Experience [0.03%]
早期乳腺癌使用电子线IOERT治疗的长期结果：韦罗纳大学医院的经验
Nunzia Luna Valentina Cernusco,Paola Del Bianco,Mario Romano et al.
Nunzia Luna Valentina Cernusco et al.
Methods and materials: From July 2006 to December 2015, 295 patients suitable for breast-conserving therapy entered a single-arm phase II study and were treated with IOERT as radical treatment. Inclusion criteria were age...
A Comparison of the Oncological Outcomes After Breast-Conserving Surgery With or Without Latissimus Dorsi Myocutaneous Flap Reconstruction for Breast Cancer [0.03%]
乳腺癌保留乳房手术后带或不带背阔肌皮瓣重建的肿瘤学结果比较研究
Ryu Tokui,Makoto Ishitobi,Tomoyuki Kurita et al.
Ryu Tokui et al.
Background: There is little information on the oncological outcomes of breast-conserving surgery (BCS) with immediate reconstruction using a latissimus dorsi myocutaneous flap (LDMF) for breast cancer compared with BCS al...
Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer [0.03%]
结合雌激素受体和孕激素受体水平可以预测人表皮生长因子受体阳性早期乳腺癌患者的预后结局
Mengdi Chen,Jiayi Wu,Deyue Liu et al.
Mengdi Chen et al.
Background: In human epidermal growth factor receptor 2 (HER2)-positive breast cancer, emerging evidence imply that clinical behaviors differ according to hormone receptor (HR) status. However, there is no conclusion abou...
Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis [0.03%]
曲美替尼治疗HER2阳性乳腺癌脑转移患者的成本效益分析（基于美国）
Liangliang Dong,Shen Lin,Lixian Zhong et al.
Liangliang Dong et al.
Purpose: To evaluate the cost-effectiveness of tucatinib in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) patients with brain metastases (BMs) and the subgroup of active BMs from the United S...